U.S. Water Utilities Stock News

Gold Resource Corporation reported a past fourth‑quarter 2025 operational turnaround at its Don David Gold Mine, with higher‑grade ore from the Three Sisters area driving record silver sales and a shift toward silver‑weighted production. This operational improvement marks a meaningful change in the company’s revenue mix, increasing its exposure to silver‑linked performance at the Don David operation. We’ll now look at how this operational turnaround and Three Sisters’ higher‑grade ore shape...

If you are wondering whether Power Integrations is attractively priced or still has work to do before looking compelling, its recent price moves and valuation checks give you some useful clues. The share price last closed at US$42.90, with returns of 4.9% over the past week and 17.3% over the past month. The year to date return is 15.0% and the 1-year return is a 30.9% decline. Recent coverage has focused on how Power Integrations fits into the wider semiconductor space and how investors are...

Dave (NasdaqGM:DAVE) has appointed Nima Khajehnouri, Meta’s VP of Engineering, to its Board of Directors. The move brings additional AI and data engineering expertise to the company during an ongoing board reshuffle. The appointment is part of Dave’s push to deepen its technical leadership in the neobanking space. For you as an investor, this board change comes at a time when Dave’s stock has seen sharp moves. Shares recently closed at $185.27, with a 1 year return of 103.8% and a 3 year...

Earlier this week, Reliance Industries reported Q3 results that grew revenue but missed market expectations, as retail EBITDA growth slowed and margins eased while the oil and gas segment saw declines in revenue and EBITDA. Despite solid contributions from Jio Platforms and the oil-to-chemicals business, investor attention has focused on how competitive pressures and higher costs are reshaping the profitability profile of Reliance’s retail operations. Next, we’ll explore how the earnings...

If you are trying to work out whether NextDecade's current share price still reflects its long term potential, the key question is how the stock stacks up against its underlying value. The share price closed at US$4.86 recently, after a 7.4% decline over the last week and a 11.3% decline over the last month, with the one year return at a 46.3% loss and the five year return at 78.7%. Recent news around NextDecade has focused on its role in US liquefied natural gas projects and its efforts to...

If you are wondering whether SLM's share price still reflects good value after its long run as a student lending name, you are not alone. The stock last closed at US$26.00, with returns of a 3.1% decline over 7 days, a 4.9% decline over 30 days, a 5.1% decline year to date, and a 7.4% decline over 1 year. The 3 year and 5 year returns sit at 65.1% and 120.9% respectively. Recent coverage has focused on how SLM fits into the broader student loan and consumer credit conversation, with...

Edgewise Therapeutics (EWTX) updated investors on its late stage pipeline, outlining 2026 milestones for muscular dystrophy and cardiovascular programs. These include key sevasemten trial readouts and a potential future New Drug Application submission. See our latest analysis for Edgewise Therapeutics. The update on 2026 clinical milestones comes as Edgewise Therapeutics trades at $28.73, with a 90 day share price return of 92.95% and a 3 year total shareholder return of 160.24%. This...

If you are wondering whether VeriSign's share price still reflects fair value or if expectations have run ahead of the fundamentals, you are in the right place. VeriSign shares most recently closed at US$248.12, with returns of 0.7% over the last 7 days, 1.7% over the last 30 days, 3.2% year to date and 18.9% over 1 year, while the 3 and 5 year returns sit at 16.1% and 27.7% respectively. These price moves sit against a backdrop of ongoing attention on domain infrastructure providers and the...

If you are wondering whether Paycom Software's current share price lines up with its underlying value, you are not alone. This article is built to help you size that up clearly. The stock closed at US$147.48, with returns of a 6.4% decline over 7 days, a 9.4% decline over 30 days, a 3.2% decline year to date and a 29.0% decline over 1 year, alongside a 53.0% decline over 3 years and a 61.6% decline over 5 years, which may have shifted how investors view its risk and potential reward. Recent...

If you are looking at Qorvo and wondering whether the current share price reflects fair value or an opportunity, you are not alone. The stock last closed at US$79.85, with returns of a 0.5% decline over 7 days, a 6.8% decline over 30 days, a 7.4% decline year to date and an 8.8% decline over 1 year, alongside longer term returns of a 26.1% decline over 3 years and a 54.4% decline over 5 years. Recent attention on Qorvo has centered on how these share price moves fit with its position in the...

Option Care Health (OPCH) has drawn fresh attention after expanding its share repurchase authorization to US$1b, completing earlier buybacks, and issuing full year 2026 net revenue guidance of US$5.8b to US$6.0b. See our latest analysis for Option Care Health. Those announcements come after a strong run in the share price, with a 30 day share price return of 10.09% and a 90 day share price return of 26.51%, while the 1 year total shareholder return of 21.45% and 5 year total shareholder...

Earlier this month, National Vision Holdings, Inc. reaffirmed its earnings guidance for the 53 weeks ended January 3, 2026, maintaining expected net revenue between US$1.97 billions and US$1.99 billions. This confirmation of the revenue outlook reinforces management’s confidence in the company’s operating trajectory and offers investors increased clarity on near-term expectations. Next, we’ll examine how National Vision’s decision to reaffirm full-year earnings guidance shapes the company’s...

As the United States market experiences a rebound following recent volatility, with major indices like the Dow Jones and S&P 500 showing significant gains after addressing geopolitical tensions, investors are keeping a close eye on high-growth sectors. In this dynamic environment, identifying tech stocks with strong fundamentals and innovative potential can be crucial for navigating the opportunities presented by such market fluctuations.

Amid recent volatility in the U.S. markets, with major indices like the Dow Jones and S&P 500 experiencing significant fluctuations due to geopolitical tensions and economic policy shifts, investors are keenly observing opportunities that may arise from these movements. In such an environment, identifying stocks that are potentially undervalued based on intrinsic value estimates can offer a strategic advantage, as they might provide growth potential when market conditions stabilize.

Major stock indexes saw a significant rebound recently, with the Dow Jones adding 450 points after President Trump ruled out the use of force in Greenland. Amidst this backdrop of market volatility and geopolitical tensions, investors are exploring opportunities beyond traditional stocks. Penny stocks, often representing smaller or newer companies, continue to attract attention for their potential value and growth prospects. In this article, we explore three penny stocks that showcase...

UFP Industries recently reported that unit sales have fallen over the past two years, with earnings per share dropping faster than revenue and returns on capital slipping, pointing to past profit pools becoming harder to sustain. This combination of weaker volumes, compressed earnings, and declining capital efficiency raises fresh questions about how durable the company’s profit engine may be. Next, we’ll examine how the ongoing slide in earnings per share shapes UFP Industries’ investment...

Corvus Pharmaceuticals recently reported positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of oral soquelitinib in moderate to severe atopic dermatitis, and confirmed plans to start a Phase 2 study in the first quarter of 2026. The cohort 4 data are particularly interesting because they show clinical activity in patients who had previously failed systemic treatments, including dupilumab and JAK inhibitors, while maintaining a favorable safety profile...

Disc Medicine recently faced a two-week postponement of the U.S. FDA’s review of its rare disease candidate bitopertin, as regulators raised questions about efficacy endpoints, data integrity, and potential abuse risk. At the same time, the company appointed industry veteran Lisa Amaya Price as Chief Human Resources Officer, signaling an effort to strengthen its organizational backbone as it prepares for possible commercialization. Next, we’ll examine how the FDA’s temporary review delay for...

Reverse split reshapes Ozop Energy Solutions share structure Ozop Energy Solutions (OZSC) is carrying out a 1 for 5,000 reverse stock split effective January 21, 2026. This move sharply consolidates its share count and changes the trading price per share. This type of corporate action does not alter the company’s reported revenue of US$0.32 million or its loss of US$6.95 million, but it can influence liquidity, trading behavior, and how different investors view the stock. See our latest...

Omega Healthcare Investors (NYSE:OHI) is showing a strong technical breakout pattern, pointing to renewed investor interest in the healthcare REIT space. The breakout aligns with a confirmed uptrend and a solid technical setup that traders may use as a rule-based entry signal. With shares last closing at $45.04, the move is drawing fresh attention from investors watching healthcare focused real estate names. For context, Omega Healthcare Investors has delivered a 28.1% return over the past...

If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with a 5.7% return, but has seen shorter term pullbacks with a 2.5% decline over 7 days and a 3.4% decline over 30 days, while the 3 and 5 year figures sit at 14.2% and 15.7% respectively. Recent headlines around Abbott Laboratories have focused on its position in medical devices and diagnostics, as...

If you are wondering whether Origin Bancorp's current share price reflects solid value or hidden risk, it helps to start by lining up the recent performance with what you are actually paying for the business. The stock last closed at US$39.70, with returns of 1.1% over 7 days, 2.1% over 30 days, 5.5% year to date, 13.1% over 1 year, 8.7% over 3 years, and 47.1% over 5 years. This gives useful context before comparing the price to fundamentals. Recent coverage has focused on Origin Bancorp's...

If you are trying to figure out whether Bilibili is attractively priced today, the key question is whether the recent share price reflects its underlying fundamentals or leaves room for value. Bilibili last closed at US$30.27, with a 7 day return of 3.6% decline, a 30 day return of 22.2% and a 1 year return of 77.5%, which sits alongside a 3 year return of 18.1% and a 5 year return of 76.0% decline. These moves sit against ongoing investor focus on Chinese tech and media names, where risk...

Gap Inc. (NYSE:GAP) has created a new Chief Entertainment Officer role and appointed Pam Kaufman. The company is launching a "Fashiontainment" approach that connects its brands more closely with entertainment and media. Gap is establishing an entertainment focused hub in Los Angeles to anchor content, partnerships, and collaborations. The first major licensing effort under this push is the Artist Series, featuring Robert Indiana's LOVE artwork. Gap Inc. (NYSE:GAP) is known for its core...